4''-hexyloxy-[1,1':4',1'']terphenyl-4-carboxylic acid | 158938-09-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4''-hexyloxy-[1,1':4',1'']terphenyl-4-carboxylic acid
• 英文别名: 4-(4-(4-(hexyloxy)phenyl)phenyl)benzoic acid；4-[4-(4-Hexoxyphenyl)phenyl]benzoic acid
• CAS: 158938-09-1
• 化学式: C₂₅H₂₆O₃
• 分子量: 374.48
• InChiKey: WVVDWFOBAXDLRE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.1
• 重原子数：
  28
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4''-hexyloxy-[1,1':4',1'']terphenyl-4-carboxylic acid 在 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 N-[(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S,26S)-6-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,21,25-tetrahydroxy-3,15-bis[(1R)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-18-yl]-4-[4-(4-hexoxyphenyl)phenyl]benzamide
  参考文献：
  名称：

  抗真菌脂肽类棘球菌素B（ECB）的半合成化学修饰：ECB的多芳基酰基类似物的亲脂性和几何参数的结构活性研究。

  摘要：

  Echinocandin B（ECB）是由亚油酸在N端酰化的复杂环状肽组成的脂肽。ECB的酶促脱酰作用提供了肽“核”作为无生物活性的底物，通过N端的化学酰化作用可从中产生新的ECB类似物。酰基的变化揭示了侧链的结构和物理性质，特别是其几何形状和亲脂性，在确定类似物的抗真菌效力方面起着关键作用。使用CLOGP值描述和比较侧链片段的亲脂性，表明抗真菌活性的表达要求> 3.5。其次，侧链的线性刚性几何形状是增强抗真菌效力的最有效形状。使用这些参数作为指导，合成了多种新型ECB类似物，其中包括结合了联苯，三联苯，四联和芳乙炔基的芳基。通常，这些类似物对葡聚糖合酶的抑制与体外和体内活性密切相关，并且同样受侧链结构的影响。这些结构变化导致在体外和体内测定中抗真菌活性的增强。这些类似物中的一些，包括LY303366（14a），通过口服途径有效。通常，这些类似物对葡聚糖合酶的抑制与体外和体内活性密切相关，

  DOI：

  10.1021/jm00017a012
• 作为产物：
  描述：

  1-carbomethoxy-4''-(hexyloxy)terphenyl 在 sodium hydroxide 作用下， 以 1,4-二氧六环 为溶剂， 反应 17.0h， 生成 4''-hexyloxy-[1,1':4',1'']terphenyl-4-carboxylic acid
  参考文献：
  名称：

  抗真菌脂肽类棘球菌素B（ECB）的半合成化学修饰：ECB的多芳基酰基类似物的亲脂性和几何参数的结构活性研究。

  摘要：

  Echinocandin B（ECB）是由亚油酸在N端酰化的复杂环状肽组成的脂肽。ECB的酶促脱酰作用提供了肽“核”作为无生物活性的底物，通过N端的化学酰化作用可从中产生新的ECB类似物。酰基的变化揭示了侧链的结构和物理性质，特别是其几何形状和亲脂性，在确定类似物的抗真菌效力方面起着关键作用。使用CLOGP值描述和比较侧链片段的亲脂性，表明抗真菌活性的表达要求> 3.5。其次，侧链的线性刚性几何形状是增强抗真菌效力的最有效形状。使用这些参数作为指导，合成了多种新型ECB类似物，其中包括结合了联苯，三联苯，四联和芳乙炔基的芳基。通常，这些类似物对葡聚糖合酶的抑制与体外和体内活性密切相关，并且同样受侧链结构的影响。这些结构变化导致在体外和体内测定中抗真菌活性的增强。这些类似物中的一些，包括LY303366（14a），通过口服途径有效。通常，这些类似物对葡聚糖合酶的抑制与体外和体内活性密切相关，

  DOI：

  10.1021/jm00017a012

文献信息

• Lipopeptide Compounds and Their Use
  申请人：Boyce Rustum S.

  公开号：US20110224129A1

  公开（公告）日：2011-09-15

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain lipopeptide compounds comprising a cyclic peptide bearing a lipid side chain (for convenience, collectively referred to herein as “LP compounds”), which, inter alia, are antimicrobial, particularly antibacterial. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to provide an antimicrobial function, particularly an antibacterial function, and in the treatment of diseases and conditions that are mediated by microbes, particularly bacteria, that are ameliorated by the antimicrobial function, particularly an antibacterial function, including bacterial diseases, optionally in combination with another agent, for example, another antibacterial agent.

  本发明一般涉及治疗化合物领域，更具体地涉及包括带有脂肪侧链的环肽的某些脂肽化合物（为方便起见，在本文中统称为“LP化合物”），其中，这些化合物具有抗微生物作用，特别是抗菌作用。本发明还涉及包括这些化合物的药物组合物，以及使用这些化合物和组合物，在体外和体内提供抗微生物功能，特别是抗菌功能，以及在治疗由微生物介导的疾病和病症方面的用途，特别是由抗菌功能缓解的细菌疾病，可选地与另一药剂（例如另一抗菌剂）结合使用。
• Total synthesis and structure–activity relationships of caspofungin-like macrocyclic antifungal lipopeptides
  作者：Jianzhong Yao、Hongming Liu、Ting Zhou、Hai Chen、Zhenyuan Miao、Guoqiang Dong、Shengzheng Wang、Chunquan Sheng、Wannian Zhang

  DOI：10.1016/j.tet.2012.02.015

  日期：2012.4

  The echinocandins represent a well-known class of macrocyclic antifungal lipopeptides that can be used for treatment of invasive fungal infections. Due to their complex chemical structures and synthetic difficulties, the structure activity relationships (SARs) of them are still limited. A total synthetic approach was developed to synthesize structurally diverse caspofungin-like antifungal cyclic lipopeptides, allowing for systemically investigating their SARs. Most of the designed cyclic lipopeptides showed potent antifungal activities with broad spectrum. In particular, several compounds (e.g., 30a, 30e-h, 31a-d, 32c, and 33a,b) were more active in vitro against Candida albicans or Aspergillus fumigatus than caspofungin. The findings in this work indicated that the 'left' tripeptide segment of cyclic lipopeptide scaffold might be suitable for a hydrophilic structural motif, whereas the 'right' lipotripeptide segment was preferred as a hydrophobic core. The alkoxy-naphthoyl was found to be optimal side chain and alkyl length could affect the SARs of alkoxy-aroyl side chains. (C) 2012 Elsevier Ltd. All rights reserved.
• LIPOPEPTIDE COMPOUNDS AND THEIR USE
  申请人：Merlion Pharmaceuticals Pte Ltd.

  公开号：EP2350119A1

  公开（公告）日：2011-08-03
• US8921309B2
  申请人：——

  公开号：US8921309B2

  公开（公告）日：2014-12-30
• [EN] LIPOPEPTIDE COMPOUNDS AND THEIR USE<br/>[FR] COMPOSÉS DE LIPOPEPTIDES ET UTILISATION DE CEUX-CI
  申请人：MERLION PHARMACEUTICALS PTE LT

  公开号：WO2010062264A1

  公开（公告）日：2010-06-03

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain lipopeptide compounds comprising a cyclic peptide bearing a lipid side chain (for convenience, collectively referred to herein as "LP compounds"), which, inter alia, are antimicrobial, particularly antibacterial. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to provide an antimicrobial function, particularly an antibacterial function, and in the treatment of diseases and conditions that are mediated by microbes, particularly bacteria, that are ameliorated by the antimicrobial function, particularly an antibacterial function, including bacterial diseases, optionally in combination with another agent, for example, another antibacterial agent.